<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Cecilia</forename><surname>Bozzetti</surname></persName>
							<email>cecilia.bozzetti@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<orgName type="institution">Charité Campus Mitte</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Seval</forename><surname>Türkmen</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Institute für Humangenetik</orgName>
								<address>
									<addrLine>Labor Berlin</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Charité Vivantes GmbH</orgName>
								<address>
									<addrLine>Sylter Straße 2</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Richter</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<orgName type="institution">Charité Campus Mitte</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Fransecky</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Charité</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Hindenburgdamm 30</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gürkan</forename><surname>Bal</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institut für Transfusionsmedizin</orgName>
								<orgName type="institution">Charité Campus Virchow Klinikum</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten-Oliver</forename><surname>Schulz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<orgName type="institution">Charité Campus Mitte</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Hemmati</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Charité Campus Virchow Klinikum</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Arnold</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Charité Campus Virchow Klinikum</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hanno</forename><surname>Riess</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<orgName type="institution">Charité Campus Mitte</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Charité Campus Virchow Klinikum</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Le Coutre</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<orgName type="institution">Charité Campus Mitte</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Charité Campus Virchow Klinikum</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Charité Campus Mitte</orgName>
								<orgName type="institution" key="instit2">Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie</orgName>
								<address>
									<addrLine>Schumannstr. 20/21</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F8755868CB6532B5CB09E757B901FFEF</idno>
					<note type="submission">Received: December 3, 2015 Revised: January 22, 2016 Accepted: February 2, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:22+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>acute myeloid leukemia</term>
					<term>translocation (2;3)</term>
					<term>3q26</term>
					<term>EVI1</term>
					<term>anagrelide</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We hereby report a case of acute myeloid leukemia with translocation t(2;3) and involvement of the ectopic virus integration site-1 (EVI1) gene.</s><s>Like most other 3q26-related disorders reported thus far, we describe a phenotype with elevated platelet counts and dysmegakaryopoesis.</s><s>The clinical course of our patient was complicated by symptomatic thrombophilia and chemoresistance.</s><s>In addition, our case exhibited FLT3 (Fms-related tyrosine kinase 3) internal tandem duplication.</s><s>Although anagrelide was successful in controlling elevated platelet counts, allogeneic stem cell transplantation failed to overcome chemoresistance due to simultaneous graft-versus-host-disease and relapse of acute myeloid leukemia.</s><s>Given the dismal outcome of our case and previously reported cases, we propagate the implementation of targeted therapies to newly diagnosed patients with acute myeloid leukemia t(2;3).</s><s>Preclinical models indicate drugs that plausibly target the EVI1-related molecular vulnerability as candidates for basket trials.</s><s>Anagrelide exhibited a hopeful signal of activity in 3q26-related thrombocytosis and should be evaluated for implementation as supportive care.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Diagnosis of acute myeloid leukemia (AML) is currently made by bone marrow cytology and is significantly augmented by immunophenotypic and molecular genetic studies.</s><s>Pre-therapeutic disease classification mostly depends on cytogenetic analyses: many recurrent cytogenetic abnormalities harbor not only prognostic but also predictive value. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>e WHO classification of AML currently includes seven recurrent cytogenetic abnormalities.</s><s>One of those is rare and involves the chromosome 3 characterized by inv(3) (q21;q26.2) or t(3;3)(q21;q26.2) and constitutes a subgroup of AML with dismal outcome.</s></p><p><s>We hereby report on a patient with de-novo AML presenting a rare, but recurrent cytogenetic abnormality: t(2;3) (p21;q26) with involvement of the ectopic virus integration site-1 (EVI1).</s><s>To our knowledge, there are only 17 cases of AML with t(2;3) reported to this date (Table <ref type="table" target="#tab_0">1</ref>), <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> which resemble some properties of inv(3) and t(3;3) AML.</s><s>This case report should expand our understanding of biology, risk and prognosis of AML with t(2;3).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CASE REPORT</head><p><s>Here we report on a 48-year-old male without a history of prior malignancy or chronic illness who was admitted to our hospital with recent onset of skeletal discomfort.</s><s>The paraclinical work-up included leukocytosis (40/nL), thrombocytosis (1,174/nL) and elevated lactate dehydrogenase (540 U/ L).</s><s>The morphological assessment of the peripheral blood revealed 25% myeloblasts (Fig. <ref type="figure" target="#fig_0">1A</ref>) and a bone marrow aspiration was performed that resulted in the diagnosis of AML (Fig. <ref type="figure" target="#fig_0">1B</ref>) with an unremarkable immunophenotype (CD13 + , CD33 + , CD34 + , CD117 + , myeoloperoxidase + ).</s><s>Conventional cytogenetics analysis (Fig. <ref type="figure" target="#fig_0">1C</ref>) revealed the presence of a translocation 46,XY,t(2;3)(p21;q26) [20]/46,XY [2] including the EVI1 locus as detected by fluorescence in situ hybridization (Fig. <ref type="figure" target="#fig_0">1D</ref>).</s><s>Moreover, we identified an internal tandem duplication of FLT3 (Fms-related tyrosine kinase 3) (FLT3-ITD [FLT3-internal tandem duplication] + ) but no other molecular marker typically present in AML (mixed lineage leukemia -, nucleophosmin 1 -, CEBPA [CCAAT/enhancer binding protein (C/EBP), α] -).</s><s>Intensive induction chemotherapy with a classical DA 7+3 regimen (i.e.</s><s>cytarabine: 100 mg/m 2 , days 1-7, daunorubicine: 60 mg/ m 2 , days 3-5) was started including prophylactic anticoagulation due to the elevated platelet count.</s><s>Chemotherapy associated complications included neutropenic sepsis with pneumonia of the right upper lobe.</s><s>Disease related complications were catheter-associated deep venous thrombosis of the right internal jugular vein and bilateral pulmonary embolism (Fig. <ref type="figure" target="#fig_1">2B</ref>).</s><s>Clinical resolution of all treatment-related complications was achieved by conservative measures and platelet counts decreased to 25/nL on day 13 of first induction.</s><s>The sharp increase of platelet counts thereaft er was reflected by a suboptimal response as assessed by bone marrow aspiration on day 16 exhibiting an aplastic marrow with a significant population of residual myeloblasts.</s></p><p><s>Consequently, we initiated a salvage chemotherapy with FLAG-Ida (i.e.</s><s>fludarabine: 30 mg/m 2 , days 1-5; idarubicine: 10 mg/m 2 , days 1-3; cytarabine 2,000 mg/m 2 days 1-5) and interpreted declining platelet counts during this course as an indication for disease control.</s><s>While tolerability was acceptable, blood counts failed to reconstitute and remission assessment by bone marrow biopsy confirmed refractory disease with a subtotal infiltration of the bone marrow by myeloblasts.</s></p><p><s>We fast-tracked allogenic stem cell transplantation in aplasia from a matched related donor and successfully bridged to transplant with a third induction cycle in analogy to the MICE protocol (i.e.</s><s>mitoxantrone: 7 mg/m 2 , days 1, 3, 5; etoposide 100 mg/m 2 , days 1-3; cytarabine 100 mg/m 2 , days 1-7).</s><s>Clinical and paraclinical characteristics of patients diagnosed with AML with t(2;3) as previously reported by a Stevens-Kroef, et al., <ref type="bibr">3 b</ref> Trubia, et al. <ref type="bibr" target="#b4">5</ref> and c Yamamoto, et al. <ref type="bibr" target="#b3">4</ref> including the hereby reported case * .</s><s>Survival in months from the time point of diagnosis.</s><s>SCT, stem cell transplantation; #, SCT was performed in 5 of 6 cases reported by Turbia et al.</s></p><p><s>At this point, we successfully controlled platelet counts until transplantation with anagrelide (1 mg/day, bidaily)(Fig.</s><s><ref type="figure" target="#fig_1">2A</ref>), which is regularly used for the treatment of patients with essential thrombophilia.</s><s>Notably, anagrelide was effective, even though we detected a thrombopoietin serum concentration only marginally above normal. <ref type="bibr" target="#b5">6</ref></s><s>llogenic hematopoietic stem cell transplantation from his HLA-identical brother (10/10-Ag) was performed 60 days after diagnosis using FLAMI/RIC conditioning (fludarabine 30 mg/m 2 , days 1-4, cytarabine 2,000 mg/m 2 , days 1-4, mitoxantrone 10 mg/m 2 , days 1-4, total body irradiation 4 Gy, day 8, cyclophosphamide 60 mg/m 2 , days 9-10).</s><s>Therapy associated complications included neutropenic fever, BK-virus associated cystitis and a severe mucositis (common toxicity criteria [CTC] grade III/IV).</s><s>On day 22 after transplantation, the patient developed an acute cutaneous graftversus-host disease (CTC grade I) which responded rapidly to glucocorticoids.</s><s>On day 14 after transplantation, blood counts reconstituted and the bone marrow biopsy performed at day 28 after transplantation exhibited complete remission.</s></p><p><s>However, only a couple of days after discharge on day 42 post allogeneic stem cell transplantation, the patient was admitted due to deteriorating liver function tests and exanthema.</s><s>Moreover, platelet counts were again on the rise and  a bone marrow workup consecutively confirmed relapse with myeloblast infiltration, mixed donor chimerism (85%), and r e -e m e rg i n g t r a n s l o c a t i o n 4 6 , X Y, t ( 2 ; 3 ) ( p 2 1 ; q 2 6 ) [2]/46,XY [1] (only three metaphases could be analysed).</s><s>Once more, anagrelide was used to control platelet counts.</s><s>We clinically diagnosed exanthema and decreasing liver function tests as acute hepatic and cutaneous graft versus host disease (GvHD) (both CTC grade III).</s><s>Challenged by simultaneous relapse and GvHD, we increased immunosuppression.</s><s>Unfortunately, we detected replication of cytomegalovirus (CMV) in the peripheral blood (CMV status donor: IgM negative, IgG positive, CMV status recipient: IgM negative, IgG positive) and pneumocystis jirovecii pneumonia.</s><s>Shortly after, the patient succumbed with hepatic and respiratory failure secondary to acute hepatic GvHD and infectious complication with underlying smoldering relapse of AML.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The identification of prognostic and ultimately predictive markers to decide upon treatment intensity has become a standard procedure in heterogeneous malignancies like AML.</s><s>While some recurrent cytogenetic aberrations have been proven to justify treatment intensification by e.g.</s><s>up-front allogenic stem cell transplantation, the impact of less common genetic abnormalities often remain unclear.</s></p><p><s>Our patient exhibited a rare, but recurrent translocation of the short arm of chromosome 2 and 3q26, the distal part of chromosome 3. Implicated in the more common t(3;3) (q21;q26) and inv(3)(q21q26), 3q26-related disorders share paraclinical features such as dysmegakaryopoesis and elevated platelet counts; 7 a finding that also holds true for our patient.</s><s>Therefore, it is tempting to assume a common pathobiological mechanism related to EVI1, the gene mapping to 3q26.</s><s>Indeed, t(3;3) and inv(3) were found to rearrange an oncogenic distal GATA2 enhancer on 3q21 resulting in ectopic EVI1 activation and concomitant GATA2 haploinsufficiency. <ref type="bibr" target="#b6">7</ref></s><s>Accordingly, in AML with t(2;3), ectopic expression of EVI1 was observed in most cases, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5</ref> albeit involvement of the oncogenic GATA2 enhancer seems unlikely to contribute to EVI1 overexpression in this entity as assessed by breakpoint analyses of 3q26.</s><s>However, breakpoint analyses of the short arm of chromosome 2 have failed to identify a common pathobiological mechanism as of yet. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5</ref></s><s>ur report reinforces the notion made by previous reports, that AML with t(2;3)(p21;q26) including the EVI1 locus is associated with symptomatic thrombophilia, chemoresistance and adverse risk. <ref type="bibr" target="#b3">4</ref></s><s>n a clinical level, we conclude that the occurrence of AML with t(2;3)(p21;q26) warrants up-front treatment intensification as induction chemotherapy alone failed to induce complete remission.</s><s>To improve success rates of allogeneic transplantation, we believe new therapeutic approaches should be implemented in AML with high EVI1 expression.</s><s>In preclinical models, all-trans retinoic acid (ATRA), <ref type="bibr" target="#b7">8</ref> the CD52 antibody <ref type="bibr" target="#b8">9</ref> and the BET bromodomain inhibitor JQ1 <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> have shown promising results in EVI1 positive AML.</s><s>We believe that the combination of different treatment approaches, such as ATRA and induction chemotherapy, might be a valuable option.</s><s>Moreover, anagrelide was safe and effective for the treatment of thrombocytosis.</s><s>This case study demonstrates once again, how molecularly informed therapies may challenge randomized controlled trials due to ever smaller patient cohorts.</s><s>To improve the dismal outcome of patients with rare subtypes of cancer, new forms of clinical trials (e.g.</s><s>basket trials, umbrella trials, n-of-1 trials) are required.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Cytomorphological and cytogenetic assessment of acute myeloid leukemia.</s><s>(1A) The blood smear revealed peripheral myeloblasts and excess of platelets (Pappenheim stain, x50).</s><s>(1B) Dysmegakaryopoesis with excess of immature megakaryocytes in the bone marrow (Pappenheim stain, x50).</s><s>(1C) Karyotyping at first diagnosis exhibiting t(2;3)(p21;q26) (indicated by arrows).(1D)</s><s>Fluorescence in situ hybridization analyses confirmed translocation t(2;3)(p21;q26) and implicated the ectopic virus integration site-1 (EVI1) locus by detecting breakpoints at t(2;3)(p21;q26).</s></p></div></figDesc><graphic coords="3,45.03,103.26,505.22,157.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Clinical characteristics.</s><s>(2A) Platelet counts from first diagnosis (d0) to d126 indicated clinical activity of acute myeloid leukemia.</s><s>(2B) Computed tomography scan revealed thrombosis of the superior vena cava (indicated by arrow) and right pulmonary embolism (indicated by * ).</s></p></div></figDesc><graphic coords="3,42.47,330.60,510.34,207.07" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Summary of clinical data of patients with t(2;3) acute myeloid leukemia (AML)</s></p></div></figDesc><table><row><cell cols="4">Diagnosis Age Sex Survival</cell><cell>Platelets (x10 9 /L)</cell><cell>Dysmega-karyopoesis</cell><cell>SCT</cell><cell>Karyotype</cell></row><row><cell>AML a</cell><cell>51</cell><cell>M</cell><cell>5</cell><cell>211</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p21-23;q26-27),idic(6)(q12)</cell></row><row><cell>AML a</cell><cell>42</cell><cell>M</cell><cell>6</cell><cell>196</cell><cell>-</cell><cell>-</cell><cell>46,XY,t(2;3)(p21-23;q26-27),del(5q),del(7q)</cell></row><row><cell>t/AML a</cell><cell>68</cell><cell>M</cell><cell>9</cell><cell>44</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p21-23;q26-27)</cell></row><row><cell>AML a</cell><cell>30</cell><cell>F</cell><cell>26</cell><cell>166</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p21-23;q26-27),del(5)(q31)</cell></row><row><cell>AML a</cell><cell>45</cell><cell>F</cell><cell>10</cell><cell>368</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p21-23;q26-27)</cell></row><row><cell>AML a</cell><cell>12</cell><cell>M</cell><cell>15</cell><cell>115</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p22;q26)</cell></row><row><cell>AML a</cell><cell>48</cell><cell>F</cell><cell>5</cell><cell>NA</cell><cell>+</cell><cell>-</cell><cell>45,XY,t(2;3)(p16;q26),-7</cell></row><row><cell>t/AML a</cell><cell>63</cell><cell>F</cell><cell>22</cell><cell>60</cell><cell>+</cell><cell>-</cell><cell>48,X,-X,t(2;3)(p13;q28),+4,del(5)(q14q34),-7,+8,-13,-17,add(17)(p13),+3-4mar[cp4]</cell></row><row><cell>AML a</cell><cell>53</cell><cell>F</cell><cell>12</cell><cell>72</cell><cell>-</cell><cell>-</cell><cell>45,XX,t(2;3)(p15-21;q26-27),del(7)(q11q32),del(12)(p12),-21[cp29]</cell></row><row><cell>AML a</cell><cell>68</cell><cell>F</cell><cell>8</cell><cell>7</cell><cell>+</cell><cell>-</cell><cell>43-45,XX,t(2;3)(p15-21;q26-27),-5,-7,-15,del(17)(q?),-22,+1-4mar[cp13]</cell></row><row><cell>AML b</cell><cell>36</cell><cell>M</cell><cell>4 to 14</cell><cell>130</cell><cell>-</cell><cell>#</cell><cell>46,XY,t(2;3)(p21;q27),45,XY,idem,-7,46,XY</cell></row><row><cell>AML b</cell><cell>36</cell><cell>F</cell><cell>4 to 14</cell><cell>54</cell><cell>+</cell><cell>#</cell><cell>46,XX,t(2;3)(p21;q26),48,XX,idem,+15,+22</cell></row><row><cell>AML b</cell><cell>50</cell><cell>F</cell><cell>4 to 14</cell><cell>171</cell><cell>+</cell><cell>#</cell><cell>46,XX,t(2;3)(p15;q27)</cell></row><row><cell>AML b</cell><cell>55</cell><cell>M</cell><cell>4 to 14</cell><cell>8</cell><cell>NA</cell><cell>#</cell><cell>47,XY,t(2;3)(p22;q27),+14</cell></row><row><cell>AML b</cell><cell>36</cell><cell>M</cell><cell>4 to 14</cell><cell>137</cell><cell>NA</cell><cell>#</cell><cell>46,XY,t(2;3)(p21;q27)</cell></row><row><cell>AML b</cell><cell>59</cell><cell>M</cell><cell>4 to 14</cell><cell>104</cell><cell>NA</cell><cell>#</cell><cell>46,XY,t(2;3)(p21;q26)</cell></row><row><cell>AML c</cell><cell>56</cell><cell>M</cell><cell>NA</cell><cell>2,191</cell><cell>+</cell><cell>-</cell><cell>46,XY,t(2;3)(p22;q26.2)</cell></row><row><cell>AML *</cell><cell>48</cell><cell>M</cell><cell>4</cell><cell>1,117</cell><cell>+</cell><cell>+</cell><cell>46,XY,t(2;3)(p2?1;q26)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Detailed description of paraclinical characteristics at baseline</s></p></div></figDesc><table><row><cell>Whole blood count</cell><cell></cell><cell>Clinical chemistry</cell></row><row><cell>Leu cocyte [nL]</cell><cell>40</cell><cell>Lactate dehydrogenase [U/L] 537</cell></row><row><cell>Promyelocytes [%]</cell><cell>1</cell><cell>Cytology</cell></row><row><cell></cell><cell></cell><cell>Bone marrow: 90% cellularity, 60% myeloblasts, Dysplastic</cell></row><row><cell>Matamyelocytes [%]</cell><cell>3</cell><cell>granulopoiesis and erythropoiesis, Dysmegakaryopoiesis</cell></row><row><cell></cell><cell></cell><cell>with micromegakaryocytes</cell></row><row><cell>Myelocytes [%]</cell><cell>0</cell><cell>Immunophenotype</cell></row><row><cell>Neutrophilic bandform granulocytes [%]</cell><cell>12</cell><cell>CD13 + CD33 + CD34 + CD117 + MPO + HLA-DR +/-</cell></row><row><cell cols="2">Neutrophilic hypersegmented granulocytes [%] 52</cell><cell>Molecular genetics</cell></row><row><cell>Lymphocytes [%]</cell><cell>3</cell><cell>FLT3-ITD + ; FLT3 -TKD -; MLL -; NMP1 -; CEBPA -</cell></row><row><cell>Reactive lymphatic cells [%]</cell><cell>3</cell><cell>Cytogenetics</cell></row><row><cell>Atypical lymphocytes [%]</cell><cell>0</cell><cell>46,XY,t(2;3)(p21;q26)[20]/46,XY[2]</cell></row><row><cell>Prolymphocytes [%]</cell><cell>0</cell><cell></cell></row><row><cell>Plasma cells [%]</cell><cell>0</cell><cell></cell></row><row><cell>Monocytes [%]</cell><cell>1</cell><cell></cell></row><row><cell>Eosinophils [%]</cell><cell>0</cell><cell></cell></row><row><cell>Basophiles [%]</cell><cell>0</cell><cell></cell></row><row><cell>Erythroblasts [%]</cell><cell>2.9</cell><cell></cell></row><row><cell>Fragmentocytes [%]</cell><cell>0.6</cell><cell></cell></row><row><cell>Myeloblasts [%]</cell><cell>25</cell><cell></cell></row><row><cell>Reticulocytes [%]</cell><cell>1.73</cell><cell></cell></row><row><cell>Immature platelets [%]</cell><cell>5.1</cell><cell></cell></row><row><cell>Heboglobin [g/dl]</cell><cell>13.1</cell><cell></cell></row><row><cell>Mean corpuscular volume [fL]</cell><cell>97</cell><cell></cell></row><row><cell>Platelet [nL]</cell><cell>1,117</cell><cell></cell></row><row><cell>Cytochemistry</cell><cell>POX + , Esterase -</cell><cell></cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INFORMED CONSENT</head><p><s>The patient gave his consent for publication of this case report and any accompanying images prior to his death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>The authors declare no conflict of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>COMPETING INTERESTS</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHORS' CONTRIBUTIONS</head><p><s>UR, COS, PH, RA and HR participated in the patient's treatment and collected clinical data.</s><s>ST carried out cytogenetic and fluorescence in situ hybridization analyses.</s><s>GB carried out the analysis of thrombopoietin serum concentration.</s><s>LF provided images of cytological analysis and critically reviewed the manuscript.</s><s>CB and PL designed and carried out the patient's treatment and wrote the manuscript.</s><s>All authors have read and approved the final manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mrózek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Oncol Clin North Am</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1135" to="1161" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</title>
		<author>
			<persName><forename type="first">H1</forename><surname>Döhner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Appelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Büchner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="453" to="474" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Translocation t(2;3) (p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stevens-Kroef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Poppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Zelderen-Bhola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Blij-Philipsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1108" to="1114" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Marked thrombocytosis and dysmegakaryopoiesis in acute myeloid leukemia with t(2;3)(p22;q26.2) and EVI1 rearrangement</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sanada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yakushijin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Matsuoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="1713" to="1715" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Trubia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Albano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cavazzini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Cambrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Quarta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="48" to="54" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Serum thrombopoietin level in various hematological diseases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Usuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Iki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Endo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stem Cells</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="558" to="565" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gröschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hoogenboezem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Bouwman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="369" to="381" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid</title>
		<author>
			<persName><forename type="first">B</forename><surname>Steinmetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hackl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Slabáková</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schwarzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Smějová</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Cycle</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2931" to="2943" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nakahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yamakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kaneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ichihara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="921" to="931" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Rappaport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Herrmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">478</biblScope>
			<biblScope unit="page" from="524" to="528" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Delwel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="42" to="52" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
